All In Biotech

Drug Trial Radar · NCT03649152

Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan

A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of Propagermanium in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving Irbesartan

Last checked: Nov 19, 2026Latest source record: Jul 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Nov 8, 2018

Primary completion

Jun 16, 2020

Study completion Jul 13, 2020

Sponsor

Lead sponsor
Dimerix Bioscience Pty LtdIndustry
Sponsor type
Industry
Collaborators
IQVIA Pty Ltd
First posted
Aug 28, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be evaluating the safety and efficacy of propagermanium for the treatment of participants with FSGS who are already taking irbesartan by: * monitoring symptoms that participants may experience while on the study, * measuring levels of protein in participant's urine and kidney function during the course of the study, * measuring the levels of propagermanium and irbesartan that enters into participant's urine and blood, and * comparing the propagermanium outcomes to participants' pre-study and placebo outcomes. Eligible participants will randomly be assigned to one of two arms to receive both the propagermanium and placebo in different orders as follows, either: Treatment Period 1 taking a propagermanium capsule twice a day for 16 weeks, followed by a six week washout period followed by Treatment Period 2 taking a placebo capsule twice a day for 16 weeks. OR Treatment Period 1 taking a placebo capsule twice a day for 16 weeks, followed by a six week washout period followed by Treatment Period 2 taking a propagermanium capsule twice a day for 16 weeks.

Conditions

  • Focal Segmental Glomerulosclerosis

Interventions

  • PropagermaniumDrug

    Immediate release capsule

  • PlaceboDrug

    Placebo capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Number of Adverse Events with the Adjunct use of Propagermanium Compared to Placebo in Participants with FSGS who are Receiving IrbesartanTime frame: Sixteen weeks

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Renal Research

    Gosford, New South Wales, Australia

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • Westmead

    Westmead, New South Wales, Australia

  • Sunshine Coast University Hospital

    Birtinya, Queensland, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Box Hill Hospital

    Box Hill, Victoria, Australia

  • Austion Hospital

    Heidelberg, Victoria, Australia

  • Sunshine Hospital

    Melbourne, Victoria, Australia

  • Melbourne Renal Research Group

    Melbourne, Victoria, Australia

  • Epworth Hospital

    Richmond, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.